Pharmaceutical News

RSS

Researchers can silence mutated gene responsible for Huntington's with single drug treatment

With a single drug treatment, researchers at the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine can silence the mutated gene responsible for Huntington's disease, slowing and partially reversing progression of the fatal neurodegenerative disorder in animal models.

21 Jun 2012

Review describes new classes of drugs that target androgens in novel ways

Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects.

21 Jun 2012

FDA ODAC votes in favor of Onyx’s Kyprolis

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) determined by a vote of 11-0 with 1 abstention that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis.

21 Jun 2012

Nouveau Life launches Azul Instant supplement for erectile dysfunction

Nouveau Life Pharmaceuticals Inc., a provider of quality all-natural dietary supplements, announced today the release of its Azul Instant supplement.

21 Jun 2012

FimH antagonists can effectively treat UTIs

A potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics is being reported in ACS' Journal of Medicinal Chemistry. It involves so-called FimH antagonists, which are non-antibiotic compounds and would not contribute to the growing problem of antibiotic resistance bacteria.

21 Jun 2012

Sun exposure, vitamin D and pancreatic cancer risk

High levels of ultraviolet radiation at an individual's birth location, sun-sensitive skin type and a history of skin cancer each decreased risk for pancreatic cancer, according to study results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.

20 Jun 2012

Lobbying sinks efforts to impose restrictions on painkillers

Pharmacists and drugstores appear to have undone an effort to impose more strict controls on drug controls. Meanwhile, Accretive Health, the Chicago-based hospital-billing company which is under fire, is fighting back.

20 Jun 2012

Supreme Court rules drug firms don't have to pay overtime to sales reps

The 5-4 opinion by Justice Samuel Alito says the sales representatives are not subject to the overtime pay provisions of the Fair Labor Standards Act.

20 Jun 2012

WHO releases programmatic update on antiretroviral treatment as prevention of HIV, TB

"The potential for antiretroviral medicine to reduce transmission of HIV and tuberculosis has been demonstrated, but the challenges of using treatment to prevent infection will need to be tackled country by country, and with focus on people for whom it will have the biggest impact, the latest bulletin on HIV treatment from the World Health Organization says," the Center for Global Health Policy's "Science Speaks" blog reports.

20 Jun 2012

Combination therapy may help defeat pancreatic cancer

Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.

20 Jun 2012

Emergence of drug resistance to ARVs has potential to 'curb, and even reverse' gains against HIV

Noting that the "roll-out of antiretroviral treatment for HIV in sub-Saharan Africa has been accompanied by rising rates of drug resistance," Raph Hamers, a global health research fellow at the Academic Medical Centre of the University of Amsterdam, and colleagues "call for improved patient management and the integration of population-based drug resistance surveillance into national treatment programs" in this BMJ analysis.

20 Jun 2012

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).

20 Jun 2012

KPT-SINEs might offer new treatment for people with acute leukemia

A novel family of experimental agents that blocks a molecule from shuttling proteins out of the cell nucleus might offer a new treatment for people with acute leukemia, according to a study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

20 Jun 2012

Grunenthal to commercialize Horizon Pharma's DUEXIS in Latin America

Horizon Pharma, Inc. a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that it entered into an exclusive agreement with Grunenthal for the commercialization of DUEXIS in Latin America.

19 Jun 2012

FDA, EMA grant orphan drug designation to bluebird bio's gene therapy product for adrenoleukodystrophy

bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, announced today that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted an orphan drug designation to its investigational gene therapy product for the treatment of adrenoleukodystrophy (ALD).

19 Jun 2012

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.

19 Jun 2012

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).

19 Jun 2012

US Court of Appeals confirms District Court decision in Watson's Sanctura XR patent suit

Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.

19 Jun 2012

Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

Pfizer Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for tafamidis meglumine.

19 Jun 2012

Mylan's new online resource seeks to dispel common misconceptions about generic drugs

Mylan Pharmaceuticals ULC, the Canadian subsidiary of Mylan Inc., announced today the introduction of a new online resource, ChoosingGenerics.ca, to help Canadians learn more about the value, reliability and quality of generic pharmaceuticals. The website is a public awareness tool that seeks to dispel common misconceptions and help Canadians learn more about the benefits of generic drugs.

18 Jun 2012

Pharmaceutical News

Researchers can silence mutated gene responsible for Huntington's with single drug treatment

Review describes new classes of drugs that target androgens in novel ways

FDA ODAC votes in favor of Onyx’s Kyprolis

Nouveau Life launches Azul Instant supplement for erectile dysfunction

FimH antagonists can effectively treat UTIs

Sun exposure, vitamin D and pancreatic cancer risk

Lobbying sinks efforts to impose restrictions on painkillers

Supreme Court rules drug firms don't have to pay overtime to sales reps

WHO releases programmatic update on antiretroviral treatment as prevention of HIV, TB

Combination therapy may help defeat pancreatic cancer

Emergence of drug resistance to ARVs has potential to 'curb, and even reverse' gains against HIV

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

KPT-SINEs might offer new treatment for people with acute leukemia

Grunenthal to commercialize Horizon Pharma's DUEXIS in Latin America

FDA, EMA grant orphan drug designation to bluebird bio's gene therapy product for adrenoleukodystrophy

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

US Court of Appeals confirms District Court decision in Watson's Sanctura XR patent suit

Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

Mylan's new online resource seeks to dispel common misconceptions about generic drugs

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News